13.70
前日終値:
$13.53
開ける:
$13.48
24時間の取引高:
717.35K
Relative Volume:
0.77
時価総額:
$1.04B
収益:
-
当期純損益:
$-119.67M
株価収益率:
-5.0183
EPS:
-2.73
ネットキャッシュフロー:
$-97.30M
1週間 パフォーマンス:
-3.11%
1か月 パフォーマンス:
-12.07%
6か月 パフォーマンス:
+11.29%
1年 パフォーマンス:
+12.57%
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
名前
Mineralys Therapeutics Inc
セクター
電話
(888) 378-6240
住所
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
MLYS
Mineralys Therapeutics Inc
|
13.70 | 1.04B | 0 | -119.67M | -97.30M | -2.73 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-06-11 | 開始されました | Jefferies | Hold |
2024-07-10 | 開始されました | H.C. Wainwright | Buy |
2024-04-02 | 開始されました | Goldman | Buy |
2023-03-07 | 開始されました | BofA Securities | Buy |
2023-03-07 | 開始されました | Credit Suisse | Outperform |
2023-03-07 | 開始されました | Evercore ISI | Outperform |
2023-03-07 | 開始されました | Guggenheim | Buy |
2023-03-07 | 開始されました | Stifel | Buy |
2023-03-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Mineralys Therapeutics Inc (MLYS) 最新ニュース
Mineralys stock holds Buy rating at H.C. Wainwright after CKD trial - Investing.com Canada
Mineralys enhances lorundrostat data package ahead of planned NDA - The Pharma Letter
Mineralys Therapeutics (MLYS): Analyst Reiterates Buy Rating and Price Target | MLYS Stock News - GuruFocus
Promising Trial Results for Lorundrostat Boost Mineralys Therapeutics’ Investment Appeal - TipRanks
Mineralys reports positive phase 2 data for lorundrostat in CKD By Investing.com - Investing.com South Africa
Mineralys reports positive phase 2 data for lorundrostat in CKD - Investing.com Australia
Mineralys Therapeutics Shares Climb on Strong Results from Kidney Disease Trial - MSN
Positive Phase II Results for Mineralys Therapeutics’ Lorundrostat Support Buy Rating - TipRanks
Promising Phase 2 Trial Results for Mineralys Therapeutics’ Lorundrostat Support Buy Rating and $42 Price Target - TipRanks
Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps - Benzinga
Transcript : Mineralys Therapeutics, Inc.Special Call - MarketScreener
Mineralys Therapeutics stock jumps after positive kidney disease trial data By Investing.com - Investing.com South Africa
Mineralys Therapeutics' Phase 2 Explore-CKD Study Of Lorundrostat Meets Primary Goal - Nasdaq
Mineralys Phase 2 Trial of Hypertension, Kidney Disease Drug Meets Primary Endpoint; Shares Up Pre-Bell - MarketScreener
Mineralys Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria - GlobeNewswire
Breakthrough: Mineralys Phase 2 Drug Achieves Dual Success in Blood Pressure and Kidney Protection Trial - Stock Titan
How the (MLYS) price action is used to our Advantage - news.stocktradersdaily.com
Mineralys Therapeutics (NASDAQ:MLYS) Cut to Sell at Wall Street Zen - Defense World
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Jefferies Initiates Coverage on Mineralys Therapeutics (MLYS) with Hold Rating | MLYS Stock News - GuruFocus
Jefferies Initiates Coverage on Mineralys Therapeutics With Hold Rating, $15 Price Target - MarketScreener
Jefferies initiates Mineralys Therapeutics stock with hold rating By Investing.com - Investing.com Nigeria
Jefferies initiates Mineralys Therapeutics stock with hold rating - Investing.com
Cautious Outlook for Mineralys Therapeutics Amid Market Challenges and Competitive Pressures - TipRanks
Bank of America Corp DE Has $1.33 Million Stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
BNP Paribas Financial Markets Buys Shares of 3,895 Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys Therapeutics: Merits A Small 'Speculative' Holding (NASDAQ:MLYS) - Seeking Alpha
ProShare Advisors LLC Takes Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Purchased by Deutsche Bank AG - Defense World
Mineralys Therapeutics Reveals Promising Phase 3 Results for Hypertension Drug Lorundrostat - MSN
Mineralys Therapeutics to Present Phase 3 Data on Lorundrostat at European Hypertension Meeting - MSN
Mineralys announces late-breaking presentation of data from Launch-HTN trial - Yahoo Finance
Buy Rating for Mineralys Therapeutics: Strong Clinical Results and Growth Prospects Highlight Significant Upside Potential - TipRanks
Mineralys reports outcomes from trial of lorundrostat for hypertension - Yahoo Finance
MLYS: Promising Phase 3 Results for Hypertension Treatment | MLYS Stock News - GuruFocus
Northern Trust Corp Purchases 1,688 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) - The Manila Times
Mineralys Therapeutics Reports Positive Results from Phase 3 Launch-HTN Trial of Lorundrostat for Uncontrolled Hypertension - Nasdaq
These 3 Artificial Intelligence (AI) Stocks Look Cheap Right Now - The Globe and Mail
Mineralys Therapeutics Inc Says Lorundrostat Shows 16.9 Mmhg Reduction At Week 6, 19.0 Mmhg At Week 12 - marketscreener.com
Mineralys Therapeutics Announces Late-Breaking Presentation - GlobeNewswire
Breakthrough Phase 3 Results: New Drug Cuts Blood Pressure by 19 mmHg in Largest Hypertension Trial - Stock Titan
Mineralys Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going - sharewise
Mineralys to present lorundrostat trial data at ESH 2025 - Investing.com Australia
Mineralys to present lorundrostat trial data at ESH 2025 By Investing.com - Investing.com South Africa
Mineralys Announces Late-Breaking Presentation Of Phase 3 Launch-HTN Trial - marketscreener.com
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection - The Manila Times
Mineralys Therapeutics Inc (MLYS) 財務データ
収益
当期純利益
現金流量
EPS
Mineralys Therapeutics Inc (MLYS) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Rodman David Malcom | Chief Medical Officer |
Jun 13 '25 |
Sale |
14.60 |
11,366 |
165,931 |
101,651 |
大文字化:
|
ボリューム (24 時間):